Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Melanoma is the most fatal type of skin cancer which can cause the death of victims at the
advanced stage. Extensive work has been presented by the researcher on computer vision …

Background Liquid biopsy has been widely researched for early diagnosis, prognostication
and disease monitoring in lung cancer, but there is a need to investigate its clinical utility for …

The liquid biopsy includes the detection of circulating tumor cells (CTCs) and CTC clusters
in blood, as well as the detection of, cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) …

Abstract Purpose: Neoadjuvant anti–PD-1 therapy has shown promise for resectable non–
small cell lung cancer (NSCLC). We reported the first phase I/II trial of neoadjuvant …

Targeted therapy has stepped into the perioperative treatment arena and launched a radical
revolution in the treatment of early-stage oncogene-driven non-small-cell lung cancer …

Circulating tumor DNA (ctDNA) sensitivity remains subpar for molecular residual disease
(MRD) detection in bladder cancer patients. To remedy this problem, we focused on the …

Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy
after surgery as standard‐of‐care treatment, even though only approximately 5.8% of …

Immune‐related toxicities, otherwise known as immune‐related adverse events (irAEs),
occur in a substantial fraction of cancer patients treated with immune checkpoint inhibitors …